Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

Show more
Type
Public
HQ
San Diego, US
Founded
1993
Size (employees)
42 (est)
Biocept was founded in 1993 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold

Svp & CSO

Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr
Show all (1)
Report incorrect company information

Biocept Financials and Metrics

Biocept Financials

Biocept's revenue was reported to be $5.07 m in FY, 2017
USD

Revenue (Q1, 2018)

806.9 k

Gross profit (Q1, 2018)

(1.6 m)

Gross profit margin (Q1, 2018), %

(201.7%)

EBIT (Q1, 2018)

(6.3 m)

Market capitalization (22-Jun-2018)

15.1 m

Closing share price (22-Jun-2018)

0.2

Cash (31-Mar-2018)

9.3 m
Biocept's current market capitalization is $15.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.1 m

Cost of goods sold

9.3 m

Gross profit

(4.3 m)

Gross profit Margin, %

(84%)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

76.8 k164.9 k221.4 k662.9 k1 m1.7 m1.3 m806.9 k

Cost of goods sold

985.2 k1.2 m1.5 m1.7 m1.9 m2.1 m2.4 m2.4 m

Gross profit

(908.5 k)(994.9 k)(1.3 m)(1 m)(829 k)(446.4 k)(1.1 m)(1.6 m)

Gross profit Margin, %

(1183%)(603%)(566%)(152%)(79%)(27%)(85%)(202%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.4 m8.8 m4.6 m2.1 m

Accounts Receivable

10.6 k34.2 k129 k1.2 m

Inventories

338.7 k435.9 k484.6 k498.7 k

Current Assets

5.9 m9.6 m5.8 m4.3 m
Quarterly
USDQ3, 2017Q1, 2018

Cash

9.3 m

Accounts Receivable

1.3 m

Inventories

412.9 k491 k

Current Assets

11.8 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(15.9 m)(16.9 m)(18.4 m)(21.6 m)

Depreciation and Amortization

251.2 k261.4 k322 k575.7 k

Inventories

(401.4 k)(80.4 k)494.7 k100.9 k

Accounts Payable

(981.9 k)(51.8 k)332.7 k349.9 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

412.9 k

Accounts Payable

970.5 k612.5 k766.4 k853.3 k946.3 k1.7 m1.4 m1.8 m1.6 m
USDY, 2018

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Biocept Online and Social Media Presence

Embed Graph
Report incorrect company information

Biocept News and Updates

Future of Liquid Biopsy market discussed in new Study

Market research future published a Cooked research report on global liquid biopsy market. The global liquid biopsy market is expected to grow at a CAGR of ~ 28% during the period of 2015 to 2022. Posted via Industry Today. Follow us on Twitter @IndustryToday

Liquid Biopsy Market to Garner US$ 2.89 Bn by 2026 End

Future Market Insights has announced the addition of the “Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment, 2016-2026"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information